AU2003281325A1 - Secreted and cytoplasmic tumor endothelial markers - Google Patents

Secreted and cytoplasmic tumor endothelial markers

Info

Publication number: AU2003281325A1
Authority: AU; Australia
Prior art keywords: secreted; tumor endothelial; endothelial markers; cytoplasmic; cytoplasmic tumor
Prior art date: 2002-07-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2003281325A

Other versions

AU2003281325A8 (en

Inventor

Kenneth W. Kinzler

Brad St. Croix

Bert Vogelstein

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Johns Hopkins University

Original Assignee

Johns Hopkins University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-02

Filing date

2003-07-02

Publication date

2004-01-23

2003-07-02 Application filed by Johns Hopkins University filed Critical Johns Hopkins University

2004-01-23 Publication of AU2003281325A8 publication Critical patent/AU2003281325A8/en

2004-01-23 Publication of AU2003281325A1 publication Critical patent/AU2003281325A1/en

Status Abandoned legal-status Critical Current

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
- G01N33/5758—
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Pathology (AREA)
Biotechnology (AREA)
Tropical Medicine & Parasitology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Physiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AU2003281325A 2002-07-02 2003-07-02 Secreted and cytoplasmic tumor endothelial markers Abandoned AU2003281325A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US39302302P	2002-07-02	2002-07-02
US60/393,023		2002-07-02
US45896403P	2003-04-01	2003-04-01
US60/458,964		2003-04-01
PCT/US2003/016250 WO2004005883A2 (en)	2002-07-02	2003-07-02	Secreted and cytoplasmic tumor endothelial markers

Publications (2)

Publication Number	Publication Date
AU2003281325A8 AU2003281325A8 (en)	2004-01-23
AU2003281325A1 true AU2003281325A1 (en)	2004-01-23

Family

ID=30118367

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2003281325A Abandoned AU2003281325A1 (en)	2002-07-02	2003-07-02	Secreted and cytoplasmic tumor endothelial markers

Country Status (2)

Country	Link
AU (1)	AU2003281325A1 (en)
WO (1)	WO2004005883A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2561887B8 (en)	2003-01-14	2016-12-21	Dana-Farber Cancer Institute, Inc.	Cancer therapy sensitizer
US7294704B2 (en)	2003-08-15	2007-11-13	Diadexus, Inc.	Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US8420603B2 (en)	2004-05-14	2013-04-16	Abraxis Bioscience, Llc	SPARC and methods of use thereof
AU2006249235B2 (en)	2004-05-14	2010-11-11	Abraxis Bioscience, Llc	Sparc and methods of use thereof
DE602005016831D1 (en) *	2004-10-19	2009-11-05	Univ Kumamoto
WO2006112930A2 (en)	2005-02-18	2006-10-26	Abraxis Bioscience, Inc.	Q3 sparc deletion mutant and uses thereof
WO2008057632A1 (en)	2006-11-09	2008-05-15	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Differential gene expression in physiological and pathological angiogenesis
WO2008101118A2 (en)	2007-02-14	2008-08-21	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
JP5685773B2 (en)	2007-09-07	2015-03-18	ミートアンドライブストックオーストラリアリミテッド	Drugs with angiogenic and wound healing activity
WO2010050190A1 (en) *	2008-10-27	2010-05-06	北海道公立大学法人札幌医科大学	Molecular marker for cancer stem cell
CN101708328A (en) *	2009-11-06	2010-05-19	上海市免疫学研究所	Pharmaceutical application of CYR61 protein
SG10201604497UA (en)	2011-06-02	2016-07-28	Almac Diagnostics Ltd	Molecular Diagnostic Test For Cancer
MX2015006955A (en)	2012-12-03	2016-01-25	Almac Diagnostics Ltd	Molecular diagnostic test for cancer.
KR101535717B1 (en) *	2013-09-11	2015-07-09	연세대학교 산학협력단	Composition for pancreatic cancer diagnosis comprising complememt factor i-specific binding polypeptide or antibody
CN118086317B (en) *	2024-01-12	2025-03-25	深圳市第二人民医院(深圳市转化医学研究院)	SPARC protein gene regulatory elements, functionalized albumin nanoformulations and their applications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2416732C (en) *	2000-08-02	2016-02-09	Brad St. Croix	Endothelial cell expression patterns

2003
- 2003-07-02 WO PCT/US2003/016250 patent/WO2004005883A2/en not_active Ceased
- 2003-07-02 AU AU2003281325A patent/AU2003281325A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2003281325A8 (en)	2004-01-23
WO2004005883A2 (en)	2004-01-15
WO2004005883A3 (en)	2006-07-27

Publication	Publication Date	Title
AU2003240252A1 (en)	2003-12-02	Planar antenna and antenna system
AU2003284222A1 (en)	2004-06-03	Bioabsorbable marker having external anchoring means
AU2003235470A1 (en)	2004-01-06	Predictive markers in cancer therapy
AU2003281287A1 (en)	2004-01-23	Toxicity markers
AU2003244417A1 (en)	2003-09-02	Cellular mosfet devices and their manufacture
AU2003297421A1 (en)	2004-07-14	Advertising mat
EP1581792A4 (en)	2008-07-23	Multi-functional product markers and methods for making and using the same
AU2003268508A1 (en)	2005-04-06	Emissive highway markers
AU2003281325A1 (en)	2004-01-23	Secreted and cytoplasmic tumor endothelial markers
AU2003295355A1 (en)	2004-06-15	Anchor
AU2003214438A1 (en)	2003-10-08	Providing location dependent information
GB0225360D0 (en)	2002-12-11	Genetic markers
AU2003211112A1 (en)	2003-09-04	Secreted proteins
AU2003231827A1 (en)	2003-12-12	Pseudo-tissues and uses thereof
AU2003302173A1 (en)	2004-07-14	Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003251356A1 (en)	2004-02-16	Viral marker
AU2003222189A1 (en)	2003-10-27	Secreted proteins
AU2003245092A1 (en)	2004-01-23	Sound-absorbing material
AU2003215379A1 (en)	2003-09-09	Substituted pyrimidinones and pyrimidinthiones
AU2003240603A1 (en)	2003-11-11	Examination and demonetization system for value markers
AU2003218924A1 (en)	2003-10-27	Luminescent markers
AU2003300859A1 (en)	2004-06-30	Carrier-ligand fusions and uses thereof
AU2003248933A1 (en)	2004-02-02	Secreted proteins
AU2003267475A1 (en)	2004-04-23	Tumor targeting agents and uses thereof
AU2003216442A1 (en)	2003-09-09	Enkurin and uses thereof

Legal Events

Date	Code	Title	Description
2005-07-21	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase